Endothelin I is a 21 amino acid peptide produced primarily by vascular endothelial cells. It is also produced by renal mesangial and epithelial cells. Endothelin I has potent effects on peripheral vascular resistance, renal blood flow and glomerular filtration rate. Endothelin I appears to be a mediator of hypertension and acute renal failure of hemolytic uremic syndrome. Levels of Endothelin I are increased in patients with hemolytic uremic syndrome with hypertension anuria and oligonuria. Endothelin I has potent vasoconstriction properties. Endothelin I stimulates the oppositive vasodilator called Endothelium Derived Releasing Factor. Levels are also increased in trauma patients.
4.0 – 9.0 pg/ml
Endothelin I is measured by direct radioimmunoassay.
Patient should not be on any ACTH, Corticosteroid or hypertension medications, if possible, for at least 48 hours prior to collection of specimen.
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Minimum specimen size is 1 ml.
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.), contact the Institute for requirements and special handling.
Ship specimens frozen in dry ice.
1. RL Siegler, SS Edwin, RD Christofferson, and MD Mitchell. Endothelin in the Urine of Children with the Hemolytic Uremic Syndrome. Pediatrics 88: 1063-1066, 1991.
2. WL Miller, MM Redfield and JC Burnett Jr. Integrated Cardiac, Renal and Endocrine Actions of Endothelin. Journal of Clinical Investigations 83: 317-320, 1989.